Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On August 7, 2017, we issued a press release reporting our financial results for the second quarter ended June 30, 2017. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
|
99.1 |
Press release issued August 7, 2017, reporting financial results for the second quarter ended June 30, 2017 |
ARENA PHARMACEUTICALS INC ExhibitEX-99.1 2 arna-ex991_6.htm EX-99.1 arna-ex991_6.htm Exhibit 99.1 Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results – Achieved Positive Phase 2 Results for Ralinepag in July,…To view the full exhibit click here
About Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that target G protein-coupled receptors (GPCRs). The Company’s drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management, and is being commercialized under the brand name, BELVIQ. The Company’s drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. APD334 is an orally available modulator of the sphingosine 1-phosphate subtype 1 (S1P1) receptor intended for the treatment of multiple sclerosis, psoriasis, inflammatory bowel diseases and rheumatoid arthritis. The Company’s programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases and an undisclosed orphan GPCR for central nervous system indication(s).
